Brief: Fulcrum Therapeutics Q2 Basic EPS USD 0.89
31/07/2024 12:00
Jul 31 (Reuters) - Fulcrum Therapeutics Q2 operating expenses USD 27.508 million. * Q2 operating income USD 52.492 million vs. IBES estimate USD 361.4 thousand * Q2 collaboration revenue USD 80 million * Q2 net income USD 55.409 million
Recent news on Fulcrum Therapeutics
See all newsFulcrum down after announcing restructuring, plans to cut 85% jobs
Brief: Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Fulcrum
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Philip Morris
Fulcrum falls after discontinuing sickle cell drug program